iSAM Funds UK Ltd Takes $4.88 Million Position in Merck & Co., Inc. $MRK

iSAM Funds UK Ltd acquired a new stake in Merck & Co., Inc. (NYSE:MRK) in the third quarter, HoldingsChannel.com reports. The institutional investor acquired 58,095 shares of the company’s stock, valued at approximately $4,876,000. Merck & Co., Inc. makes up approximately 1.0% of iSAM Funds UK Ltd’s holdings, making the stock its largest holding.

Other hedge funds have also added to or reduced their stakes in the company. Brighton Jones LLC increased its holdings in shares of Merck & Co., Inc. by 29.5% in the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock worth $3,808,000 after acquiring an additional 8,710 shares in the last quarter. Sivia Capital Partners LLC grew its position in shares of Merck & Co., Inc. by 52.2% in the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock valued at $910,000 after purchasing an additional 3,941 shares during the period. Good Life Advisors LLC increased its stake in Merck & Co., Inc. by 35.9% during the 2nd quarter. Good Life Advisors LLC now owns 15,663 shares of the company’s stock worth $1,240,000 after purchasing an additional 4,141 shares in the last quarter. Oak Harvest Investment Services increased its stake in Merck & Co., Inc. by 7.7% during the 2nd quarter. Oak Harvest Investment Services now owns 58,922 shares of the company’s stock worth $4,664,000 after purchasing an additional 4,194 shares in the last quarter. Finally, Donoghue Forlines LLC raised its holdings in Merck & Co., Inc. by 17.7% during the 2nd quarter. Donoghue Forlines LLC now owns 18,341 shares of the company’s stock worth $1,452,000 after buying an additional 2,755 shares during the period. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Down 0.3%

NYSE MRK opened at $115.61 on Friday. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $125.14. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. The stock has a 50 day moving average of $115.26 and a 200-day moving average of $99.58. The company has a market cap of $285.84 billion, a PE ratio of 15.88, a PEG ratio of 2.24 and a beta of 0.27.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The business had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. During the same period in the previous year, the company earned $1.72 earnings per share. The firm’s revenue for the quarter was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, equities research analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be paid a dividend of $0.85 per share. The ex-dividend date is Monday, March 16th. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. Merck & Co., Inc.’s payout ratio is currently 46.70%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on MRK. BMO Capital Markets raised shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $82.00 to $130.00 in a research note on Thursday, December 18th. UBS Group increased their price objective on shares of Merck & Co., Inc. from $105.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Weiss Ratings restated a “hold (c)” rating on shares of Merck & Co., Inc. in a report on Monday, December 29th. TD Cowen boosted their price objective on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the company a “hold” rating in a research report on Tuesday, January 20th. Finally, Scotiabank upped their target price on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “sector outperform” rating in a research note on Thursday, December 4th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and an average target price of $126.81.

Insider Activity at Merck & Co., Inc.

In other news, CFO Caroline Litchfield sold 41,997 shares of the company’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $119.61, for a total value of $5,023,261.17. Following the sale, the chief financial officer directly owned 90,192 shares of the company’s stock, valued at approximately $10,787,865.12. This represents a 31.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Chirfi Guindo sold 20,000 shares of the firm’s stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $121.88, for a total transaction of $2,437,600.00. Following the completion of the sale, the chief marketing officer owned 80,615 shares of the company’s stock, valued at $9,825,356.20. This trade represents a 19.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 320,176 shares of company stock worth $38,281,735 over the last ninety days. Company insiders own 0.13% of the company’s stock.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Unusually large call buying: traders bought ~672,962 call options on Friday (a ~1,339% jump vs. typical daily call volume), signaling heavy bullish speculation or hedging interest that can lift near-term implied volatility and upside pressure on MRK shares.
• Positive Sentiment: Phase 3 WELIREG data and regulatory filings deepen Merck’s oncology growth story — new Phase 3 results for belzutifan (WELIREG) combos with KEYTRUDA or LENVIMA show meaningful improvement in RCC; FDA filings with priority reviews/PDUFA dates for 2026 could expand label and revenue runway. Merck’s WELIREG Kidney Cancer Trials Deepen Oncology Growth Story
• Positive Sentiment: Analyst upgrades/price-target raises: Wells Fargo raised its price target to $150 and assigned an overweight rating, and Leerink lifted its target as well — both moves increase institutional demand signals and implied upside for MRK. Benzinga Leerink Raises Merck & Co. Inc. (MRK) Price Target
• Positive Sentiment: RBC Capital maintains a Buy rating, reinforcing analyst support and potentially bolstering demand from long-only managers. RBC Capital Sticks to Its Buy Rating for Merck & Company (MRK)
• Positive Sentiment: Bullish price commentary: coverage and price-target pieces (e.g., 247WallStreet) argue broader upside (some scenarios to $150) based on drug pipeline potential, supporting a favorable narrative among momentum investors. Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150
• Neutral Sentiment: Market report on Ovidrel/Ovitrelle highlights expanding fertility market opportunities that could be a modest long-term tailwind for related Merck products, but it’s not an immediate revenue catalyst. Ovidrel or Ovitrelle Market Research Report 2026
• Neutral Sentiment: Misc. coverage items (e.g., stock-picking lists and unrelated biotech moves) mention MRK in broader contexts but are unlikely to materially move the stock on their own. 1 Unpopular Stock That Deserves Some Love and 2 We Avoid ImmunityBio Stock Soars 295% YTD

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.